Discovery Life Sciences

Glenn Bilawsky has served as CEO since 2016, having repositioned the company from a focused lab into a multi-division biospecimen and analytics platform. The company was acquired by private equity firm Astorg in 2022 from prior investors. It operates as a for-profit contract research organization, not a single-family office or university-affiliated institute, serving pharmaceutical sponsors through integrated laboratory and logistics divisions.

The company's repository, pegged at approximately 2 million human biospecimens as of 2022 (per public record), covers solid tumor tissue, blood components, bone marrow, and non-oncology disease-state materials including cardiovascular and neurological indications. Specimens are sourced through a consented donor network and clinical site partnerships, with linked de-identified patient outcomes used for biomarker validation and companion diagnostic programs.

Discovery integrates both. Its Biomarker Services division generates multi-omics data — including next-generation sequencing, spatial transcriptomics, multiplex immunohistochemistry, and proteomics — from its biobanked and client-provided specimens. This dual model separates the firm from pure-specimen brokers, enabling a single-provider workflow from tissue acquisition through assay-ready datasets.

The firm's Cell & Gene Therapy Solutions unit supplies leukopaks, whole blood, and isolated cell products including CD3+ and CD34+ selections. It runs flow cytometry, potency assays, and process-development support for autologous and allogeneic therapy programs, typically engaging at the preclinical through early clinical stage.

Financial terms of the 2022 Astorg acquisition were not publicly disclosed, and the company does not publish revenue or deployment figures. As a privately held, sponsor-backed entity, it is valued on its laboratory capacity, specimen inventory scale, and contractual pharma partnerships rather than a publicly reported asset base.

While the firm's primary client base includes 8 of the top 10 global pharmaceutical companies, its procurement network and laboratory services are also available to academic medical centers, government research programs, and clinical cooperative groups through standard master services agreements.

The company executed over a dozen acquisitions from 2018 onward, absorbing firms including Conversant Bio, the HudsonAlpha Institute for Biotechnology's clinical sequencing laboratory, and QualTek Molecular Laboratories. This inorganic expansion built its dual physical presence in Huntsville and Pennsylvania, added European lab capacity, and consolidated a fragmented biospecimen broker market under one operational umbrella.